Skip to content

Diagnostic Value of Serum Cathepsin S and Chromogranin A in DKD

Diagnostic Value of Serum Cathepsin S and Chromogranin A in Diabetic Kidney Disease

Status
Not yet recruiting
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06069076
Enrollment
92
Registered
2023-10-05
Start date
2023-11-01
Completion date
2026-10-01
Last updated
2023-10-13

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Diabetic Kidney Disease

Brief summary

1. Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease. 2. To correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.

Detailed description

Diabetic nephropathy (DN) is a common and serious complication of diabetes and has been shown to be a major cause of end-stage renal disease (ESRD), requiring costly renal replacement therapy in the form of dialysis or transplantation . It is appreciated that up to 40% of patients with type 1 and type 2 diabetes mellitus (DM) present DN . Early detection and appropriate treatment are essential to prevent disability and death. Cathepsin S (Cat-S) was a secreted cysteine proteolytic enzyme that is mainly expressed in macrophages. Macrophages undergoing chemotaxis adhere to the basement membrane of blood vessels and secrete Cat-S, and the secreted Cat-S was involved in hydrolysis of elastin, laminin, collagen and other extracellular matrix components, causing vascular damage . So, Cathepsin S(Cat-S), a novel non-invasive diagnostic marker mediates vascular endothelial dysfunction. In recent years, studies have shown that up regulation of Cat-S was associated with the development of IgA nephropathy, lupus nephritis, insulin resistance, diabetes and other renal diseases. Chromogranin A (CgA) is the main member of the chromogranin family and is an acidic glycoprotein consisting of 439 amino acids with an approximate molecular mass of 48 kDa. CgA is used as a diagnostic marker of neuroendocrine tumors(6). The kidney is the main site for the removal of CgA, and it is retained in serum with declining renal function. In patients with renal failure, serum CgA increases much more than creatinine and the other studied low-MW proteins.

Interventions

DIAGNOSTIC_TESTcathepsin S and chromogranin A

Diagnostic value of serum Cathepsin S and Chromogranin A

Sponsors

Assiut University
Lead SponsorOTHER

Study design

Observational model
CASE_CONTROL
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
20 Years to 80 Years
Healthy volunteers
Yes

Inclusion criteria

* patients diagnosed as type 2 Diabetes mellitus * Patients with T2DM with normoalbuminuria , microalbuminuria and macroalbuminuria.

Exclusion criteria

* Renal impairment of other Known origin, * Type 1 D, * Hepatic disease, * Heart failure, * Thyroid disorders, * Autoimmune disorders, * Inflammatory condition, * Malignancy, * Urinary tract infection, * Pregnancy.

Design outcomes

Primary

MeasureTime frameDescription
Evulate the diagnostic value of serum cathepsin S and chromogranin A for Diabetic kidney disease.BaselineEvaluation of the clinical utility of the measurement of the level of Cathepsin S and chromogranin A in type 2 diabetic nephropathy.

Secondary

MeasureTime frameDescription
correlate the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.BaselineStudying the correlation of the levels of serum Cathepsin S and chromogranin A with HbA1c and eGFR in type 2 diabetic patients based on urinary Albumin- Creatinine Ratio.

Contacts

Primary ContactZeinab kamel
zozet2013@yahoo.com01060247896

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026